Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) EBT Margin (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed EBT Margin for 13 consecutive years, with 54600.0% as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, EBT Margin rose 11960000.0% year-over-year to 54600.0%, compared with a TTM value of 67883.33% through Sep 2025, up 13223333.0%, and an annual FY2024 reading of 48120.0%, up 67564000.0% over the prior year.
  • EBT Margin was 54600.0% for Q1 2025 at Alaunos Therapeutics, down from 18875.0% in the prior quarter.
  • Across five years, EBT Margin topped out at 86709.09% in Q4 2022 and bottomed at 794900.0% in Q4 2023.
  • Average EBT Margin over 5 years is 180844.08%, with a median of 41875.0% recorded in 2024.
  • The sharpest move saw EBT Margin tumbled -88160909bps in 2023, then skyrocketed 77602500bps in 2024.
  • Year by year, EBT Margin stood at 590350.0% in 2021, then skyrocketed by 115bps to 86709.09% in 2022, then crashed by -1017bps to 794900.0% in 2023, then surged by 98bps to 18875.0% in 2024, then crashed by -189bps to 54600.0% in 2025.
  • Business Quant data shows EBT Margin for TCRT at 54600.0% in Q1 2025, 18875.0% in Q4 2024, and 29150.0% in Q2 2024.